Actinium Pharmaceuticals Company Profile (NYSE:ATNM)

Analyst Ratings

Consensus Ratings for Actinium Pharmaceuticals (NYSE:ATNM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Actinium Pharmaceuticals (NYSE:ATNM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Actinium Pharmaceuticals (NYSE:ATNM)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Actinium Pharmaceuticals (NYSE:ATNM)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Actinium Pharmaceuticals (NYSE:ATNM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Actinium Pharmaceuticals (NYSE:ATNM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Actinium Pharmaceuticals (NYSE:ATNM)
DateHeadline
07/20/16 10:43 AMActinum Pharma Conducts Investigator Meeting For Phase 3 Iomab-B Sierra Trial
07/20/16 10:43 AMActinium Pharmaceuticals Highlights Successful Investigator Meeting for Pivotal Phase 3 Iomab-B SIERRA Trial
03/09/16 01:40 PMActinium Pharmaceuticals Incorporated (NYSEMKT:ATNM) Shorts Decreased by 4.94% After Short Covering - RiversideGazette.com - Actinium Pharmaceuticals Incorporated (NYSEMKT:ATNM) Shorts Decreased by 4.94% After Short CoveringRiversideGazette.comThe short interest to Actinium Pharmaceuticals Incorporated's float is 5.74%. The stock is up 1.53% or $0.03 after the news, hitting $1.99 per share. About 41,767 shares traded hands. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) has risen 16.67% since ...and more »
03/07/16 01:19 PMH.C. Wainwright Initiates Coverage on Actinium Pharmaceuticals Inc to Buy - Street Edition - H.C. Wainwright Initiates Coverage on Actinium Pharmaceuticals Inc to BuyStreet EditionH.C. Wainwright Initiates Coverage on Actinium Pharmaceuticals Inc(NYSEMKT:ATNM). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Feb 29, 2016. Actinium Pharmaceuticals Inc (ATNM) made into the market gainers list on ...
02/19/16 12:50 PMActinium Pharmaceuticals Incorporated (NYSEMKT:ATNM) Sellers Covered 2.76% of Their Shorts - RiversideGazette.com - Actinium Pharmaceuticals Incorporated (NYSEMKT:ATNM) Sellers Covered 2.76% of Their ShortsRiversideGazette.comThe short interest to Actinium Pharmaceuticals Incorporated's float is 6.04%. The stock is down 1.36% or $0.03 after the news, hitting $2.17 per share. About 46,618 shares traded hands. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) has declined 9.09% ...Big Movers: Golden Minerals Company (NYSEMKT:AUMN), Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM ...Stock Transcriptall 2 news articles »
02/03/16 12:15 PMActinium Pharmaceuticals Inc Can't Be More Risky. The Stock Formed a Multiple Bottom Pattern - WallStreet.org - Actinium Pharmaceuticals Inc Can't Be More Risky. The Stock Formed a Multiple Bottom PatternWallStreet.orgThe stock of Actinium Pharmaceuticals Inc (ATNM) shows a multiple bottoms pattern with $1.80 target or 13.00% below today's $2.07 share price. The 5 months chart pattern indicates high risk for the $89.88M company. It was reported on Feb, 3 by Finviz.com.and more »
01/27/16 12:07 PMRecent Broker Updates On Actinium Pharmaceuticals, Inc. (ATNM) - Risers & Fallers - Recent Broker Updates On Actinium Pharmaceuticals, Inc. (ATNM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Actinium Pharmaceuticals, Inc. (ATNM). The latest broker reports which are currently outstanding on Wednesday 27th January state 1 analyst has a rating of “strong buy”, ...
01/19/16 10:35 AMActinium Pharmaceuticals: A Small Cap Stock To Watch In The Biotech Space -
01/16/16 11:30 AMBiotech Stock to Watch: Actinium Pharmaceuticals Inc - iStreetWire - iStreetWireBiotech Stock to Watch: Actinium Pharmaceuticals InciStreetWireActinium Pharmaceuticals Inc (ATNM) on January 11, 2016 announced that the Company was presented at the 8th Annual Biotech Showcase today, Monday, January 11, 2016 at 9:30 am Pacific Time in Room Market Street. The Biotech Showcase is taking ...
01/11/16 07:00 AMActinium Pharmaceuticals to Present at Biotech Showcase 2016 - [Marketwired] - Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative drug candidates for the treatment of advanced cancers, announced that the Company will be presenting at the 8th Annual ...
01/09/16 04:48 AMActinium Pharmaceuticals Inc (ATNM) Short Interest Update - Actinium Pharmaceuticals Inc (NYSE:ATNM) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 2,213,758 shares, a drop of 1.1% from the November 30th total of 2,239,372 shares, MarketBeat reports.
01/09/16 04:48 AMShort Interest in Actinium Pharmaceuticals Inc (ATNM) Declines By 1.1% - Actinium Pharmaceuticals Inc (NYSE:ATNM) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,213,758 shares, a decline of 1.1% from the November 30th total of 2,239,372 shares, ARN ...
01/09/16 03:52 AMShort Interest in Actinium Pharmaceuticals Inc (ATNM) Declines By 1.1% - Actinium Pharmaceuticals Inc (NYSE:ATNM) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 2,213,758 shares, a decrease of 1.1% from the November 30th total of 2,239,372 shares ...
01/08/16 03:30 AMShort Interest in Actinium Pharmaceuticals Inc (ATNM) Drops By 1.1% - Actinium Pharmaceuticals Inc (NYSE:ATNM) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 2,213,758 shares, a drop of 1.1% from the November 30th total of 2,239,372 shares ...
01/07/16 12:02 PMThis Company is Up +400% in a Month - [Accesswire] - LAS VEGAS, NV / ACCESSWIRE / January 7, 2016 / Endonovo Therapeutics, Inc. (OTCQB:ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, ...
01/06/16 09:01 PMActinium Pharmaceuticals Inc (ATNM) Short Interest Update - Actinium Pharmaceuticals Inc (NYSE:ATNM) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 2,213,758 shares, a decrease of 1.1% from the November 30th total of ...
01/05/16 07:35 AMActinium Pharmaceuticals (ATNM) in Focus: Stock Jumps 5.3% -
01/03/16 10:39 AMShort Interest in Actinium Pharmaceuticals Inc (ATNM) Drops By 1.1% - Actinium Pharmaceuticals Inc (NYSE:ATNM) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 2,213,758 shares, a decrease of 1.1% from the November 30th total of 2,239,372 shares ...
01/03/16 10:21 AMActinium Pharmaceuticals Inc (ATNM) Short Interest Down 1.1% in December - Actinium Pharmaceuticals Inc (NYSE:ATNM) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,213,758 shares, a decline of 1.1% from the November 30th total of ...
01/03/16 10:01 AMActinium Pharmaceuticals Inc (ATNM) Short Interest Down 1.1% in December - Actinium Pharmaceuticals Inc (NYSE:ATNM) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,213,758 shares, a decline of 1.1% from the November 30th total of ...
01/03/16 07:24 AMActinium Pharmaceuticals Inc (ATNM) Sees Significant Drop in Short Interest - Actinium Pharmaceuticals Inc (NYSE:ATNM) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,213,758 shares, a decline of 1.1% from the November 30th total of ...
12/29/15 07:15 AMActinium Pharmaceuticals (ATNM) Jumps: Stock Up 7.2% -
12/28/15 06:00 AMActinium to Ring First Closing Bell of 2016 at the New York Stock Exchange - [Marketwired] - Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative drug candidates for the treatment of advanced cancers today announced that the Company will be ringing the closing bell ...
12/24/15 12:10 PMACTINIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Entry into a -
12/24/15 12:00 PMActinium and Memorial Sloan Kettering Cancer Center Sign Agreement in Respect of Certain Liquidity Matters - [Marketwired] - Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative drug candidates for the treatment of advanced cancers, and Memorial Sloan Kettering Cancer Center today announced that ...
12/22/15 07:10 AMFactors Moving Markets - Research Reports on UTStarcom Holdings, Rocket Fuel, American Midstream Partners and Actinium Pharmaceuticals - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 22, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: UTStarcom ...
12/21/15 02:52 PMPharmaceutical And LNG Stocks Are Driving The Market Higher Today -
12/17/15 11:46 AMWhy Are These Stocks Surging Amid Today’s Gloomy Market? -
12/17/15 06:00 AMActinium Announces Iomab-B IND Has Been Cleared By FDA; Pivotal, Phase 3 Trial to Proceed - [Marketwired] - Actinium Pharmaceuticals, Inc. , is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company announced today that the FDA......
12/16/15 03:11 PMACTINIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a -
12/08/15 12:16 PMACTINIUM PHARMACEUTICALS, INC. Financials -
12/08/15 07:00 AMClinical Trial Results for Actimab-A Presented at the 57th American Society of Hematology Annual Meeting - [Marketwired] - Actinium Pharmaceuticals, Inc. , is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that Dr. Joseph......

Social

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: ATNM
  • CUSIP:
Key Metrics:
  • Previous Close: $1.75
  • 50 Day Moving Average: $1.76
  • 200 Day Moving Average: $1.91
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $83.57M
  • Current Year EPS Consensus Estimate: $-0.70 EPS
  • Next Year EPS Consensus Estimate: $-0.64 EPS
Additional Links:
Actinium Pharmaceuticals (NYSE:ATNM) Chart for Saturday, July, 30, 2016